Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
  • A61K38/085—Angiotensins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention provides methods for treating a subject that has suffered combined (i) exposure to total body ionizing irradiation and (ii) burns, comprising administering to the subject an amount effective to treat the radiation effects and/or the burn of a peptide comprising at least 5 amino acids of a peptide of SEQ ID NO: 1 (Asp- Arg-Nle-Tyr-Ile-His-Pro), or a pharmaceutical salt thereof.
• the method results in improved survival in the subject compared to control.
• the method results in accelerated burn healing compared to control.
• the subject has suffered second degree burns to one or more of the trunk, back, head, arm, or leg.
• the subject has been exposed to total body ionizing irradiation of between 0.2 gray (G)y to 10 Gy; in further embodiments the subject has been exposed to total body ionizing irradiation of between 1 gray (G)y to 10 Gy or between 2 gray (G)y to 10 Gy. In another embodiment, the subject has suffered cumulative exposure to total body ionizing irradiation of at least 20 cGy. In a still further embodiment, the total body ionizing radiation is selected from the group consisting of beta-irradiation, gamma-irradiation, and X-ray.
• the total body ionizing irradiation is caused by exposure to a radiation source selected from the group consisting of nuclear weapons, nuclear power facilities, computed tomography scan devices, X-ray devices, irradiators for bone marrow transplant conditioning, nuclear powered vehicles, and environment contaminated by radioactive materials.
• the peptide is administered within three days of total body ionizing irradiation exposure.
• the peptide comprises or consists of a peptide of SEQ ID NO: 1 (Asp-Arg-Nle-Tyr-Ile-His-Pro), or a pharmaceutical salt thereof.
• Figure 7 Effect of NorLeu 3 -A( 1-7) on Survival in a Guinea Pig Model of CRBI in guinea pigs following 200 cGy TBI.
• Figure 8 Effect of NorLeu 3 -A(l -7) on Survival in a Guinea Pig Model of CRBI in guinea pigs following 200 cGy TBI .
• Figure 9 Effect of NorLeu -A(l-7) on Survival in a Guinea Pig Model of CRBI in guinea pigs following 200 cGy TBI.
• NorLeu3-A(l-7) reduces apoptosis in the dermis and subdermis of thermal injuries in a mouse model of CRBI (10 sec scald at 70C following 600 cGy TBI), but not at the site of thermal injury alone.
• the present invention provides methods for treating a subject that has suffered combined (i) exposure to total body ionizing irradiation and (ii) burns, comprising administering to the subject an amount effective to treat the radiation effects and/or the burn of a peptide comprising at least 5 amino acids of a peptide of SEQ ID NO: l (Asp- Arg-Nle-Tyr-Ile-His-Pro), or a pharmaceutical salt thereof.
• Nle A(l-7) is a peptide having the amino acid sequence Asp-Arg-Nle-Tyr-lle-His-Pro.
• the peptide comprises or consists of Asp-Arg-Nle-Tyr-Ile (Nle A(l-5)) (SEQ ID NO:3), Asp-Arg-Nle-Tyr-Ile-His (Nle A(l-6)) (SEQ ID NO:2), or Nle A(l-7).
• the invention is appropriate for use with any type of ionizing radiation exposure accompanied by burns such as therapeutic or accidental X-ray, gamma ray, or beta particle exposure.
• ionizing radiation exposure suitable for treatment with the methods of the present invention include, but are not limited to, clinical radiation therapy, medical diagnostics using radioactive tracers, exposure to naturally occurring ionizing radiation sources such as uranium and radon, wartime exposure (ie: nuclear weapons), and accidental exposures including occupational exposure at nuclear power facilities, and medical and research institutions, computed tomography scan devices, X-ray devices, irradiators for bone marrow transplant conditioning, nuclear powered vehicles, and environment contaminated by radioactive materials.
• the subject may be any suitable subject that can benefit from the methods of the invention.
• the subject is a mammal, such as a human; pets such as dogs and cats; and livestock, including but not limited to cattle, sheep, goats, pigs, and chickens.
• total body ionizing irradiation means exposure to a source of ionizing irradiation that affects multiple organ systems.
• the subject has been exposed to total body ionizing irradiation of between 0.2 gray Gy to 12 Gy or greater; in further embodiments the subject has been exposed to total body ionizing irradiation of between 1 gray Gy to 12 Gy or greater; 2 gray y to 12 Gy or greater; 0.2 Gy to 10 Gy or greater; 1 Gy to 10 Gy or greater; 2 gray (G)y to 10 Gy or greater; 2.5 Gy to 10 Gy or greater; 3 Gy to 10 Gy or greater; 3.5 Gy to 10 Gy or greater; 4 Gy to 10 Gy or greater; 4.5 Gy to 10 Gy or greater.; 5 Gy to 10 Gy or greater; 5.5 Gy to 10 Gy or greater; 6 Gy to 10 Gy or greater; 6.5 Gy to 10 Gy or greater; 7 Gy to 10 Gy or greater; 7.5 Gy to 10 Gy or greater; 8 Gy to 10 Gy or greater; 8.5 Gy to 10 Gy or greater; 9 Gy to 10 Gy or greater; greater than 10 Gy; or greater than 12 Gy.
• the subject has suffered cumulative exposure to total body ionizing irradiation of at least 20 cGy. In various further embodiments, the subject has suffered cumulative exposure to total body ionizing irradiation of at least 25 cGy, 30 cGy, 35 cGy , 40 cGy , 45 cGy ,50 cGy, 55 cGy , 60 cGy, 65 cGy, 70 cGy, 75 cGy, 80 cGy , 85 cGy , 90 cGy , 95 cGy ,100 cGy, or greater.
• the burn may be of any severity, preferably a partial thickness burn (i.e.: second- degree burn) to any body site, including but not limited to trunk, back, head, arm, or leg.
• the burn may be of any size, preferably at least 3 cm 2 in area, and more preferably at least 4, 5, 6, 7, 8, 9, or 10 cm 2 in area.
• the subject has suffered burns (such as second degree burns) over at least 10%, 20%, 30%, 40%, 50%, 60%, 79%, or more of their total body surface area.
• the administering occurs within 0, 1, 2, or 3 days of radiation exposure.
• the peptide is administered in 1 ug per wound or higher; more preferably 10 ug or higher per wound.
• the peptide is administered in a dosage of 10 ug/cm 2 , 50 ug/day, 100 ug/day, 200 ug/cm 2 , 250 ug/day, 300 ug/cm 2 , 350 ug/cm 2 , 400 ug/cm 2 , 450 ug/cm 2 , 500 ug/day, or more.
• treat means accomplishing one or more of the following: (a) reducing the severity of the burns or ionizing irradiation effects; (b) limiting or preventing development of symptoms characteristic of ionizing irradiation exposure; (c) inhibiting worsening of symptoms characteristic of ionizing irradiation exposure; (d) accelerated burn healing compared to control; and (e) improved survival.
• the biological effects of radiation depend on a number of factors such as the dose of radiation, duration of exposure, and the organ that is affected.
• Non-limiting examples of effects of exposure to total body ionizing irradiation include nausea, vomiting, diarrhea, impairment in central nervous system function (such as cognitive impairment, seizures, tremors, and ataxia), leukopenia, bone marrow destruction, intestinal destruction, infection (bacterial viral, fungal, etc.), shock, hypotension, hemorrhage, and death.
• the amount of peptide or pharmaceutical salt thereof is sufficient to provide the dosages discussed above. In exemplary embodiments, the amount of peptide or pharmaceutical salt thereof is sufficient to provide a dosage to a patient of between 0.01 ⁇ g kg and 10 mg/kg; 0.1 ⁇ g/kg and 5 mg/kg; 0.1 ⁇ g/kg and 1000 ⁇ g/kg; 0.1 ⁇ g/kg and 900 ⁇ g/kg; 0.1 ⁇ g/kg and 900 ⁇ g/kg; 0.1 ⁇ g/kg and 800 ⁇ g/kg; 0.1 ⁇ g/kg and 700 ⁇ g/kg; 0.1 ⁇ g kg and 600 ⁇ g kg; 0.1 ⁇ g kg and 500 ⁇ g kg; or 0.1 ⁇ g/kg and 400 ⁇ g kg.
• Suitable acids which are capable of forming salts with the peptide include inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like; and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid and the like.
• inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like
• organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic
• Suitable bases capable of forming salts with the peptide include inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like; and organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like) and optionally substituted ethanol-amines (e.g., ethanolamine, diethanolamine and the like).
• inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like
• organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like) and optionally substituted ethanol-amines (e.g., ethanolamine, diethanolamine and the like).
• the pharmaceutical compositions for use in the methods of the invention may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions).
• the pharmaceutical compositions may be applied in a variety of solutions. Suitable solutions for use in accordance with the invention are sterile, dissolve sufficient amounts of the Nle A(l-7), and are not harmful for the proposed application.
• the compounds of the present invention are very stable but are hydrolyzed by strong acids and bases.
• the compounds of the present invention are soluble in organic solvents and in aqueous solutions at pH 5-8.
• the pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants.
• the pharmaceutical composition is prepared for topical subcutaneous administration, the peptide or salt thereof may comprise from 0.0001% to 10% w/w; in one embodiment, not more than 5% w/w, and in a further embodiment from 0.01% to 2% w/w of the formulation.
• the peptide or salt thereof is prepared as a stable lyophilized peptide formulation that can be reconstituted with a suitable diluent to generate a
• the reconstituted formulation may be used as a multi-use formulation.
• a diluent comprising a preservative (such as bacteriostatic water for injection)
• the reconstituted formulation may be used as a multi-use formulation.
• Such a formulation is useful, for example, where the subject requires frequent subcutaneous administrations of peptide.
• the advantage of a multi-use formulation is that it facilitates ease of use for the patient, reduces waste by allowing complete use of vial contents, and results in a significant cost savings for the manufacturer since several doses are packaged in a single vial (lower filling and shipping costs).
• Such reconstituted formulations would also be suitable for use with other types of parenteral administration.
• the peptide or salts thereof can be administered by any suitable route, including but not limited to dermal, subcutaneous, intradermal, transdermal (for example, by slow-release polymers), intramuscular, intraperitoneal, intravenous, oral, aural, epidural, anal or vaginal (for example, by suppositories), and intranasal routes, infusion or bolus injection, or absorption through epithelial or mucocutaneous linings.
• the peptide or salts are administered transdermally and is formulated as a topical formulation, such as with hydroxyl ethyl cellulose (HEC).
• HEC hydroxyl ethyl cellulose
• the formulation is shielded to prevent degradation during stockpiling.
• the pharmaceutical compositions are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration.
• the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidine, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration.
• the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, carboxymethyl cellulose colloidal solutions, hydroxyethyl cellulose colloidal solutions, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers.
• Other adjuvants and modes of administration are well known in the pharmaceutical art.
• the carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.
• the peptide or pharmaceutical composition is administered topically.
• any type of topical application means may be employed that permits the influx of the peptide or pharmaceutical composition into the thermally-injured tissue over a period of time.
• an aqueous solution could be applied to the burn tissue through a gauze bandage or strip, or such a solution could be formulated so that a timed perfusion may be obtained (using liposomes, ointments, micelles, etc.)
• Methods for the production of these formulations with the peptides or pharmaceutical compositions of the present invention are apparent to those of ordinary skill in the art.
• the peptide or salts thereof can further be derivatized to provide enhanced half- life, for example, by linking to polyethylene glycol.
• the peptide or salts thereof may comprise L- amino acids, D-amino acids (which are resistant to L-amino acid-specific proteases in vivo), a combination of D- and L-amino acids, and various "designer" amino acids (e.g., ⁇ -methyl amino acids, Ca-methyl amino acids, and Na-methyl amino acids, etc.) to convey special properties.
• Synthetic amino acids include norleucine for isoleucine.
• peptide or salts thereof can have peptidomimetic bonds.
• a peptide may be generated that incorporates a reduced peptide bond, i.e., Ri-CH 2 -NH-R 2 , where Ri and R 2 are amino acid residues or sequences.
• a reduced peptide bond may be introduced as a dipeptide subunit.
• Such polypeptides are resistant to protease activity, and possess an extended half-live in vivo.
• the peptide or salts thereof may be chemically synthesized or recombinantly expressed, each of which can be accomplished using standard methods in the art.
• Nle A(l-7) or salts thereof may be administered as the sole treatment or in conjunction with other drugs or therapies useful in treating the condition in question, including but not limited to hydrogels, collagen sponges, and becaplermin gel.
• TBI total body irradiation
• Immunohistochemical staining was performed with the avidin blotin-peroxidase conjugate method. After a final rinse in PBS the sections were incubated in 0.06% 3,3'- diaminobenzidine in PBS with 0.03% hydrogen peroxide for 5 minutes. After a counterstain was performed in modified Harris' hematoxylin-eosin, the sections were dehydrated and coverslipped with Permount.
• each section of the biopsy specimen was separated into either areas on the burn edge or the actual burn areas. The entire area of the burn and edge of the burn was embedded and examined histologically. In each section four to six consecutive medium-power fields (mpf, 10 Ox) were evaluated. The cells that stained with the MIB- 1 antibody were distinct brown color. All stained cells located within the hair follicles of the biopsy sections were counted. To count the MIB- 1 stained cells each section on the slide was separated into individual medium power fields (mpf). Each field was then determined to be either a section on the edge of the burn or a part of the burn area itself.
• mpf medium-power fields
• An edge was indicated by a positive stain showing brown epithelial cells along the edge of the section.
• a burn area was indicated by an absence of brown staining cells along the edge.
• the brown cells located within each hair follicle were counted one at a time under mpf magnification. To move to the next mpf a landmark was established, and the slide then moved to the next adjacent field.
• the treatments were started immediately after the scald injury and the wound were bandaged with Tegaderm. Treatment was daily with 100 ul give per wound at a concentration of 1 mg/ml. The animals were euthanized on day 7. Apoptosis in the dermal tissue was measured by TU EL assay. Data are shown in Figure 10. NorLeu3-A(l-7) provides additional systems to mitigate delayed wound healing with the involvement of radiation.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Vascular Medicine (AREA)
• Dermatology (AREA)
• Toxicology (AREA)
• Biochemistry (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Radiation-Therapy Devices (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=43903906

Family Applications (1)

Country Status (9)

Cited By (6)

Citations (5)

Family Cites Families (4)

• 2011
  • 2011-03-28 SG SG2012070991A patent/SG184247A1/en unknown
  • 2011-03-28 JP JP2013501540A patent/JP5823486B2/ja not_active Expired - Fee Related
  • 2011-03-28 CN CN201180025747.7A patent/CN102905719B/zh not_active Expired - Fee Related
  • 2011-03-28 EA EA201201338A patent/EA022388B1/ru not_active IP Right Cessation
  • 2011-03-28 MX MX2012011036A patent/MX2012011036A/es active IP Right Grant
  • 2011-03-28 SG SG10201502348VA patent/SG10201502348VA/en unknown
  • 2011-03-28 WO PCT/US2011/030142 patent/WO2011120032A1/en not_active Ceased
  • 2011-03-28 EP EP11713415.5A patent/EP2552469B1/en not_active Not-in-force
  • 2011-03-28 US US13/637,038 patent/US9272013B2/en not_active Expired - Fee Related
  • 2011-03-28 KR KR1020127028149A patent/KR20130066598A/ko not_active Withdrawn
• 2015
  • 2015-10-07 JP JP2015199382A patent/JP2016026189A/ja not_active Withdrawn

Patent Citations (6)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events